Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Priorities for improving drug research, development and regulation

Improved R&D models, supported by appropriate regulatory pathways, are needed to provide new drugs with greater efficiency, in a framework that is financially viable for all stakeholders. Here, we present the perspective of the European Federation of Pharmaceutical Industries and Associations on the key areas on which to focus to achieve this.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Kola, I. & Bell. J. Nature Rev. Drug Discov. 10, 641–642 (2011).

    CAS  Article  Google Scholar 

  2. Orloff, J. et al. Nature Rev. Drug Discov. 8, 949–957 (2009).

    CAS  Article  Google Scholar 

  3. Breckenridge, A. et al. Nature Rev. Drug Discov. 11, 501–502 (2012).

    CAS  Article  Google Scholar 

  4. European Medicines Agency (EMA) [online], (2010).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Høngaard Andersen.

Ethics declarations

Competing interests

Susan R. Forda is an employee of Eli Lilly and owns shares in Eli Lilly and GlaxoSmithKline.

Richard Bergström receives a salary to represent the interests of pharmaceutical companies.

Magda Chlebus receives a salary to represent the interests of pharmaceutical companies.

Richard Barker is on the boards of the biopharmaceutical companies Celgene and iCo.

Peter Høngaard Andersen is an employee of Lundbeck.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Forda, S., Bergström, R., Chlebus, M. et al. Priorities for improving drug research, development and regulation. Nat Rev Drug Discov 12, 247–248 (2013). https://doi.org/10.1038/nrd3981

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3981

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing